Harmony Biosciences LLC, a private pharmaceutical company dedicated to developing and commercializing novel treatment options for people living with rare diseases, has completed a $200 million debt facility with OrbiMed Advisors LLC, an investor in the health care industry, to provide additional capital to fuel the company's continued growth.
Harmony CFO Susan L. Drexler said in a statement, "We are proud to have successfully closed on this debt facility with OrbiMed, which we believe will help support Harmony's financial growth objectives including the successful commercialization of WAKIX in the U.S."
On August 14, 2019, the U.S. Food and Drug Administration approved Harmony's first product, WAKIX® (pitolisant) tablets. Harmony continues to execute on the commercial launch of WAKIX in the U.S.
In connection with this transaction, Octagon Capital Group LLC served as financial adviser and Katten Muchin Rosenman LLP served as legal counsel to Harmony.
